ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: BCR-ABL led to proliferation disorder of CML cells in patients by activating downstream signaling.141 The current focus on discovering novel drugs against the ABL tyrosine kinase of BCR-ABL for treating CML are still ATP-competitive inhibitors.